Survival data of AURA trial

At the rapid oral abstract session at the ASCO meeting, Dr Jérémy Blanc, a medical oncologist in training from the Institut Jules Bordet, Brussels, presented the survival data from the phase II AURA trial in MIUC. This study investigates the addition of avelumab to neoadjuvant dose-dense MVAC (ddMVAC) or cisplatin-based chemotherapy, followed by surgery in the cisplatin-eligible cohort.

The trial findings indicate that incorporating neoadjuvant avelumab into cisplatin-based chemotherapy regimens significantly enhances DFS and OS at 12 and 36 months, respectively, particularly in patients achieving a complete response to the neoadjuvant treatment. The ddMVAC regimen, in combination with avelumab, demonstrates robust therapeutic activity. Conversely, cisplatin-ineligible patients exhibited lower survival outcomes at 12 months. Longer follow-up is needed for the 36-month survival analysis. Notably, achieving a pCR correlates with improved survival outcomes across all treatment arms.